DGS Capital Management LLC Acquires New Stake in Organon & Co. (NYSE:OGN)

DGS Capital Management LLC acquired a new position in Organon & Co. (NYSE:OGN - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 15,730 shares of the company's stock, valued at approximately $235,000.

A number of other large investors have also recently made changes to their positions in OGN. Prospera Private Wealth LLC bought a new stake in shares of Organon & Co. during the third quarter valued at approximately $25,000. Horizon Bancorp Inc. IN boosted its position in shares of Organon & Co. by 2,401.5% during the fourth quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company's stock valued at $25,000 after purchasing an additional 1,585 shares in the last quarter. William B. Walkup & Associates Inc. bought a new stake in shares of Organon & Co. during the second quarter valued at approximately $31,000. Versant Capital Management Inc boosted its position in shares of Organon & Co. by 92.2% during the fourth quarter. Versant Capital Management Inc now owns 2,760 shares of the company's stock valued at $41,000 after purchasing an additional 1,324 shares in the last quarter. Finally, MassMutual Private Wealth & Trust FSB boosted its position in shares of Organon & Co. by 32.4% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company's stock valued at $41,000 after purchasing an additional 672 shares in the last quarter. 77.43% of the stock is currently owned by institutional investors.

Organon & Co. Stock Down 2.7 %

NYSE:OGN traded down $0.44 during trading hours on Friday, reaching $15.97. 2,174,807 shares of the company traded hands, compared to its average volume of 2,303,732. The business's 50-day moving average price is $15.36 and its two-hundred day moving average price is $18.07. The stock has a market capitalization of $4.11 billion, a P/E ratio of 3.17, a P/E/G ratio of 0.87 and a beta of 0.76. Organon & Co. has a 1 year low of $13.87 and a 1 year high of $23.10. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73.

Organon & Co. (NYSE:OGN - Get Free Report) last announced its quarterly earnings data on Thursday, October 31st. The company reported $0.87 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.90 by ($0.03). The company had revenue of $1.58 billion for the quarter, compared to analysts' expectations of $1.56 billion. Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. The firm's quarterly revenue was up 4.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.78 EPS. Analysts predict that Organon & Co. will post 3.82 earnings per share for the current year.

Organon & Co. Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, December 12th. Stockholders of record on Tuesday, November 12th were paid a $0.28 dividend. This represents a $1.12 annualized dividend and a dividend yield of 7.01%. The ex-dividend date of this dividend was Tuesday, November 12th. Organon & Co.'s dividend payout ratio is currently 22.22%.

Analysts Set New Price Targets

Separately, TD Cowen upgraded Organon & Co. to a "hold" rating in a research report on Wednesday, January 15th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Organon & Co. currently has an average rating of "Hold" and a consensus price target of $21.33.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.